RxDoctor Payments Data

Glenn Yonemura, MD

Internal Medicine · Honolulu, HINPI 1295889798

Payments from drug & device makers

$2,791in general payments, 2019–2025

Across 160 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$319
  • Viiv Healthcare Company$310
  • Lilly USA, LLC$248
  • Novo Nordisk$248
  • Merck$217
  • Smith+Nephew$208
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,785100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,791 in reported general payments places this provider in the 80th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$63,895
Medicare patients
235
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin80$80,816
OzempicSemaglutide25$45,115
EliquisApixaban37$41,135
JanuviaSitagliptin Phosphate30$37,424
TrulicityDulaglutide15$27,482
ProliaDenosumab15$26,121
Atorvastatin Calcium530$14,782
XareltoRivaroxaban15$13,961
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$9,464
Amlodipine Besylate516$8,198
Breo ElliptaFluticasone/Vilanterol17$7,290
Wixela InhubFluticasone Propion/Salmeterol40$5,076
BrilintaTicagrelor11$4,787
SymbicortBudesonide/Formoterol Fumarate18$4,176
Losartan Potassium219$4,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$248$45,11525 claims
PfizerEliquis$174$41,13537 claims
MerckJanuvia$217$37,42430 claims
Lilly USA, LLCTrulicity$248$27,48215 claims
AmgenProlia$38$26,12115 claims
Johnson & JohnsonXarelto$173$13,96115 claims
AstraZenecaBrilinta, Symbicort$319$8,96329 claims
GSKBreo Ellipta$190$7,29017 claims
AbbVieSynthroid$150$1,77728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →